The Pharmacy Times® Immunization Resource Center is a comprehensive resource for clinical news and expert insights on common immunizations, such as flu, zoster, and COVID-19 vaccines.
April 24th 2024
The recombinant zoster vaccine demonstrated a 79.7% efficacy in patients aged 50 years and older cumulatively within the 6- to 11-year period after vaccination.
Reducing Barriers Associated With Pneumococcal Vaccine Uptake
1.5 Credits / Immunization, Infectious Diseases
View More
Reducing the Incidence and Severity of RSV in Older Adults: Opportunities for Patient Identification and Vaccination Counseling
1.0 Credit / Infectious Diseases, Pulmonology/Respiratory
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Examining the Evidence for Emerging Vaccines to Prevent RSV-Related Complications in Older Adults
2.0 Credits / Infectious Diseases, Respiratory, Immunization
View More
Influenza Prevention in the At-Risk Adult Population and the Pharmacist's Role in an Evolving Influenza Vaccine Landscape
1.25 Credits / Immunization, Infectious Disease
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
PrEPVacc HIV Vaccine Trial Halted Due to Potential Inefficacy, But Oral PrEP Regimens Continue
December 18th 2023The study, which consists of 3 trials, will continue with oral PrEP regimens; however, the vaccination trials have stopped due to the unlikely chance of the vaccine showing efficacy.
Read More
Investigational Vaccine Has Non-Inferior Immune Response Compared to PCV20 for Pneumococcal Disease
December 13th 2023Clinical trial results show the immunogenicity, tolerability, and safety of V116 compared to a pneumococcal 20-valent conjugate vaccine for adults who had not previously received a pneumococcal vaccine.
Read More
Grant Aims to Strengthen Vaccine Production in Africa
November 30th 2023By strengthening the continent's health care infrastructure, promoting local vaccine production, and facilitating global collaborations, the grant represents an important milestone toward better health care for all Africans.
Read More
FDA Approves Pentavalent Vaccine for Most Common Serogroups That Cause Meningococcal Disease
October 20th 2023Penbraya (Pfizer Inc) is the first and only approved pentavalent vaccine that confers protection against the most common meningococcal serogroups—A, B, C, W-135, and Y, in individuals 10 through 25 years of age.
Read More